57 related articles for article (PubMed ID: 14759379)
1. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).
Zhao XQ; Morse JS; Dowdy AA; Heise N; DeAngelis D; Frohlich J; Chait A; Albers JJ; Brown BG
Am J Cardiol; 2004 Feb; 93(3):307-12. PubMed ID: 14759379
[TBL] [Abstract][Full Text] [Related]
2. Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.
Goldberg RB; Bittner VA; Dunbar RL; Fleg JL; Grunberger G; Guyton JR; Leiter LA; McBride R; Robinson JG; Simmons DL; Wysham C; Xu P; Boden WE
Am J Med; 2016 Jul; 129(7):753.e13-22. PubMed ID: 27036394
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Targeted Delivery of Simvastatin and Niacin to Macrophages Using Mannan-Grafted Magnetite Nanoparticles.
Rastegari B; Ghamar Talepoor A; Khosropanah S; Doroudchi M
ACS Omega; 2024 Jan; 9(1):658-674. PubMed ID: 38222576
[TBL] [Abstract][Full Text] [Related]
4. Niacin in patients with chronic kidney disease: Is it effective and safe?
Park CW
Kidney Res Clin Pract; 2013 Mar; 32(1):1-2. PubMed ID: 26889431
[No Abstract] [Full Text] [Related]
5. Effects of extended-release niacin with laropiprant in high-risk patients.
; Landray MJ; Haynes R; Hopewell JC; Parish S; Aung T; Tomson J; Wallendszus K; Craig M; Jiang L; Collins R; Armitage J
N Engl J Med; 2014 Jul; 371(3):203-12. PubMed ID: 25014686
[TBL] [Abstract][Full Text] [Related]
6. Safety of niacin and simvastatin combination therapy.
Bays H
Am J Cardiol; 2008 Apr; 101(8A):3B-8B. PubMed ID: 18375239
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Lipid Profile and Residual Cardiovascular Risk in Patients Prior to Initiation of Niaspan Therapy.
Islam S; Danwada R; Ganguli M; Espaillat R; Jarvis M; Bacher HP
J Pharm Technol; 2018 Feb; 34(1):3-8. PubMed ID: 34860936
[No Abstract] [Full Text] [Related]
8. Niacin for primary and secondary prevention of cardiovascular events.
Schandelmaier S; Briel M; Saccilotto R; Olu KK; Arpagaus A; Hemkens LG; Nordmann AJ
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD009744. PubMed ID: 28616955
[TBL] [Abstract][Full Text] [Related]
9. Quantification of Niacin and Its Metabolite Nicotinuric Acid in Human Plasma by LC-MS/MS: Application to a Clinical Trial of a Fixed Dose Combination Tablet of Niacin Extended-Release/Simvastatin (500 mg/10 mg) in Healthy Chinese Volunteers.
Zhang P; Sun Y; Shi G; Sui Y; Li Q; Tang Y; Gu J
Int J Anal Chem; 2015; 2015():212437. PubMed ID: 26345166
[TBL] [Abstract][Full Text] [Related]
10. Hyperlipidemia medication management in patients admitted for a myocardial infarction.
Shuster JE; Jeffres MN; Barclay SM; Bhakta R
Pharm Pract (Granada); 2011 Jan; 9(1):31-6. PubMed ID: 25132887
[TBL] [Abstract][Full Text] [Related]
11. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.
Alla VM; Agrawal V; DeNazareth A; Mohiuddin S; Ravilla S; Rendell M
Drugs; 2013 Jul; 73(10):1025-54. PubMed ID: 23754124
[TBL] [Abstract][Full Text] [Related]
12. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
13. Niacin: another look at an underutilized lipid-lowering medication.
Creider JC; Hegele RA; Joy TR
Nat Rev Endocrinol; 2012 Sep; 8(9):517-28. PubMed ID: 22349076
[TBL] [Abstract][Full Text] [Related]
14. Niacin: the evidence, clinical use, and future directions.
Villines TC; Kim AS; Gore RS; Taylor AJ
Curr Atheroscler Rep; 2012 Feb; 14(1):49-59. PubMed ID: 22037771
[TBL] [Abstract][Full Text] [Related]
15. Strategies to achieve target LDL levels.
Chait A
Curr Diab Rep; 2010 Feb; 10(1):4-6. PubMed ID: 20425059
[No Abstract] [Full Text] [Related]
16. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
Parhofer KG
Vasc Health Risk Manag; 2009; 5():901-8. PubMed ID: 20016845
[TBL] [Abstract][Full Text] [Related]
17. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.
Ginsberg HN; Maccallum PR
J Clin Hypertens (Greenwich); 2009 Sep; 11(9):520-7. PubMed ID: 19751468
[TBL] [Abstract][Full Text] [Related]
18. Dyslipidemia in type 2 diabetes mellitus.
Mooradian AD
Nat Clin Pract Endocrinol Metab; 2009 Mar; 5(3):150-9. PubMed ID: 19229235
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.
Cooper-DeHoff RM; Pacanowski MA; Pepine CJ
J Am Coll Cardiol; 2009 Feb; 53(5 Suppl):S28-34. PubMed ID: 19179214
[TBL] [Abstract][Full Text] [Related]
20. Niacin plus Simvastatin Reduces Coronary Stenosis Progression Among Patients with Metabolic Syndrome Despite a Modest Increase in Insulin Resistance: A Subgroup Analysis of the HDL-Atherosclerosis Treatment Study (HATS).
Vittone F; Chait A; Morse JS; Fish B; Brown BG; Zhao XQ
J Clin Lipidol; 2007 Jul; 1(3):203-210. PubMed ID: 18591993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
